Market Cap | 4.42B | P/E | - | EPS this Y | 32.70% | Ern Qtrly Grth | - |
Income | -94.98M | Forward P/E | 42.83 | EPS next Y | 131.40% | 50D Avg Chg | 5.00% |
Sales | 820.8M | PEG | -0.09 | EPS past 5Y | - | 200D Avg Chg | 24.00% |
Dividend | N/A | Price/Book | 3.70 | EPS next 5Y | 235.60% | 52W High Chg | -17.00% |
Recommedations | 2.00 | Quick Ratio | 1.92 | Shares Outstanding | 354.37M | 52W Low Chg | 59.00% |
Insider Own | - | ROA | 0.18% | Shares Float | 145.80M | Beta | 1.11 |
Inst Own | 1.61% | ROE | -8.02% | Shares Shorted/Prior | 74.42K/73.53K | Price | 12.42 |
Gross Margin | 26.78% | Profit Margin | -11.57% | Avg. Volume | 19,138 | Target Price | 15.60 |
Oper. Margin | -6.20% | Earnings Date | - | Volume | 14,591 | Change | -4.90% |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals, as well as a strategic partnership with Dewpoint Therapeutics to advance oncology pipeline programs of condensate modifying therapeutics to investigational new drug applications and a licensing agreement with Glycotope GmbH to develop next generation immune cell engaging bispecifics for various potential indications, including solid tumors The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
HC Wainwright & Co. | Buy | Aug 31, 23 |
HC Wainwright & Co. | Buy | Jul 12, 23 |
Morgan Stanley | Overweight | Jun 23, 23 |
B of A Securities | Neutral | Jun 16, 23 |
Citigroup | Buy | Jun 8, 23 |
Morgan Stanley | Equal-Weight | Apr 4, 23 |
HC Wainwright & Co. | Buy | Mar 29, 23 |
HC Wainwright & Co. | Buy | Jan 27, 23 |
HC Wainwright & Co. | Buy | Dec 9, 22 |